Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Internal Medicine
•
Rheumatology
•
Vasculitis
How would you interpret the presence of both high titer anti-PR3 and anti-MPO antibodies in a pANCA positive patient with evidence of small vessel vasculitis?
Related Questions
How would you manage active psoriasis and psoriatic arthritis in patient on Rituximab and prednisone for MPO positive vasculitis?
How do you treat IgA cutaneous vasculitis with retiform purpura and evidence of fibrinoid necrosis on skin biopsy?
Would you consider tocilizumab for treatment of GCA in patients with underlying CLL (not requiring therapy)?
How do you approach management of a young adult after ascending thoracic aneurysm repair with biopsy showing granulomatous inflammation (no other vascular involvement, PET scan normal)?
What is your approach to patients with GCA who have difficulty with prednisone weaning (20mg) despite use of tocilizumab?
Should patients starting cyclophosphamide be screened routinely for latent tuberculosis (TB)?
How would you approach EGPA with renal involvement that was on maintenance Rituximab, last infusion two months ago and develops new onset liver involvement?
How would you approach management of a patient with a medium-to-large vessel vasculitis who developed perforation of the stomach and colon on steroids and cyclophosphamide?
Do you typically screen every patient with headaches after the age of 60 with ESR?
Do you avoid tocilizumab in patients with prior bariatric surgery given the risk of GI perforation?
